CHIEN-CHANG LEEWu Y.-H.Chung S.-H.WEN-JONE CHEN2020-12-212020-12-2120061083-7159https://scholars.lib.ntu.edu.tw/handle/123456789/529904[SDGs]SDG3allopurinol; alpha fetoprotein; creatinine; diuretic agent; glucose; insulin; lactate dehydrogenase; thalidomide; abdominal distension; abdominal pain; abnormally high substrate concentration in blood; adult; advanced cancer; alkalinization; cancer recurrence; cancer size; case report; chemoembolization; creatinine blood level; emergency ward; fatality; hemodialysis; human; hypercalcemia; hyperphosphatemia; hyperuricemia; jaundice; kidney dysfunction; kidney function; lactate dehydrogenase blood level; letter; liver cell carcinoma; low drug dose; male; metabolic acidosis; monotherapy; nephrotoxicity; priority journal; protein blood level; treatment response; tumor lysis syndrome; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Thalidomide; Tumor Lysis Syndromeletter10.1634/theoncologist.11-1-87164017192-s2.0-31444455211